#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	15250	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2508	746.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1581	1581	C	983	C,A	981,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25740	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3985	804.6	0	.	n	.	0	T695C	SNP	695	695	T	1237	1237	C	984	C,A,G	980,3,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25740	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3985	804.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1879	1879	A	1078	A,T	1077,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25740	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3985	804.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2513	2513	C	956	C,T,A	954,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25740	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3985	804.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2587	2587	A	901	A,G,C	898,2,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25740	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3985	804.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	3139	3139	C	918	C,T,G,A	915,1,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2226	folP	852	852	100.0	folP.l6.c17.ctg.1	1921	143.4	1	SNP	p	R228S	1	.	.	682	684	AGC	1214	1216	AGC	221;221;222	A;G,A;C	220;220,1;222	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5294	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3910	168.5	1	SNP	p	S91F	0	.	.	271	273	TCC	884	886	TCC	204;203;204	T;C,G;C	204;202,1;204	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5294	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3910	168.5	1	SNP	p	D95G	0	.	.	283	285	GAC	896	898	GAC	219;218;220	G,T;A;C	218,1;218;220	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5294	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3910	168.5	1	SNP	p	D95N	0	.	.	283	285	GAC	896	898	GAC	219;218;220	G,T;A;C	218,1;218;220	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.Neisseria_meningitidis_H44_76_v1_00513	mtrR.Neisseria_meningitidis_H44_76_v1_00513	1	1	27	2038	mtrR	633	633	99.84	mtrR.l6.c17.ctg.1	1742	145.3	1	SNP	p	G45D	0	.	.	133	135	GGC	678	680	GGC	237;238;239	G;G,C;C	237;237,1;239	mtrR.Neisseria_meningitidis_H44_76_v1_00513:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	332	mtrR_promoter	250	193	96.37	mtrR_promoter.l15.c4.ctg.1	1670	24.8	0	.	n	.	0	A125G	SNP	125	125	A	1011	1011	G	79	G	79	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	332	mtrR_promoter	250	193	96.37	mtrR_promoter.l15.c4.ctg.1	1670	24.8	0	.	n	.	0	C147T	SNP	147	147	C	1033	1033	T	94	T	94	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	332	mtrR_promoter	250	193	96.37	mtrR_promoter.l15.c4.ctg.1	1670	24.8	0	.	n	.	0	T159C	SNP	159	159	T	1045	1045	C	118	C	118	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	332	mtrR_promoter	250	193	96.37	mtrR_promoter.l15.c4.ctg.1	1670	24.8	0	.	n	.	0	C189T	SNP	189	189	C	1075	1075	T	108	T	108	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	332	mtrR_promoter	250	193	96.37	mtrR_promoter.l15.c4.ctg.1	1670	24.8	0	.	n	.	0	A192T	SNP	192	192	A	1078	1078	T	107	T	107	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	332	mtrR_promoter	250	193	96.37	mtrR_promoter.l15.c4.ctg.1	1670	24.8	0	.	n	.	0	A195C	SNP	195	195	A	1081	1081	C	102	C	102	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	332	mtrR_promoter	250	193	96.37	mtrR_promoter.l15.c4.ctg.1	1670	24.8	0	.	n	.	0	G221A	SNP	221	221	G	1107	1107	A	71	A	71	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5070	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3509	179.9	1	SNP	p	D86N	0	.	.	256	258	GAC	828	830	GAC	211;212;213	G;A;C	211;212;213	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5070	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3509	179.9	1	SNP	p	S87W	0	.	.	259	261	AGT	831	833	AGT	214;216;214	A,G;G;T	213,1;216;214	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5070	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3509	179.9	1	SNP	p	S87R	0	.	.	259	261	AGT	831	833	AGT	214;216;214	A,G;G;T	213,1;216;214	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5070	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3509	179.9	1	SNP	p	S87I	0	.	.	259	261	AGT	831	833	AGT	214;216;214	A,G;G;T	213,1;216;214	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5070	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3509	179.9	1	SNP	p	S88P	0	.	.	262	264	TCC	834	836	TCC	216;217;219	T,G;C,G;C,A,T	215,1;216,1;217,1,1	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4212	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3252	161.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1901	1903	GGC	231;231;232	G;G;C,G	231;231;231,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4114	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2840	180.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1463	1465	GCA	250;253;254	G;C,T;A	250;252,1;254	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4114	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2840	180.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1466	1468	ATC	254;251;251	A,C;T;C	253,1;251;251	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4114	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2840	180.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1478	1480	GTG	249;247;248	G,A;T,G;G	247,1;245,1;247	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4114	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2840	180.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1478	1480	GTG	249;247;248	G,A;T,G;G	247,1;245,1;247	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4114	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2840	180.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1982	1984	ACC	220;218;216	A;C,T;C	219;216,1;215	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4114	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2840	180.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2036	2038	GCG	228;226;228	G,C;C,G;G	227,1;225,1;228	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4114	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2840	180.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2036	2038	GCG	228;226;228	G,C;C,G;G	227,1;225,1;228	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4114	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2840	180.3	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2159	2161	GGC	221;218;219	G,A;G;C	219,1;217;219	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4114	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2840	180.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2168	2170	GGC	220;220;222	G;G;C	220;220;222	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4114	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2840	180.3	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2186	2188	CCG	234;234;232	C,G;C,T;G,C	230,4;233,1;231,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5682	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3522	200.9	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1837	1839	CTG	242;243;245	C;T,A;G	242;242,1;245	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2442	porA	1146	1146	99.83	porA.l15.c30.ctg.1	2446	124.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	909	909	C	164	C	164	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	27	3170	porB1b	1047	1047	100.0	porB1b.l6.c4.ctg.1	2048	192.6	1	SNP	p	G120K	0	.	.	358	360	GGC	912	914	GGC	267;271;276	G,T;G;C	266,1;271;276	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	27	3170	porB1b	1047	1047	100.0	porB1b.l6.c4.ctg.1	2048	192.6	1	SNP	p	D121N	0	.	.	361	363	GAC	915	917	GAC	277;276;281	G,T;A,C;C,A	276,1;275,1;280,1	porB1b.WHO_P_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	27	3170	porB1b	1047	1047	100.0	porB1b.l6.c4.ctg.1	2048	192.6	1	SNP	p	A121D	1	.	.	361	363	GAC	915	917	GAC	277;276;281	G,T;A,C;C,A	276,1;275,1;280,1	porB1b.WHO_P_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10010	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5255	237.1	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2181	2183	AAT	294;292;289	A;A,C;T,G	293;290,1;287,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1600	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1543	129.3	1	SNP	p	V57M	1	.	.	169	171	ATG	773	775	ATG	288;290;286	A;T;G	288;290;286	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
